The company said Cindy Reiss-Clark, former Senior Vice President and Chief Commercial Officer, left the company effective March 7, 2025. At the time of her departure, she was a named executive officer of the company.

1. 01

   The company said Cindy Reiss-Clark, former Senior Vice President and Chief Commercial Officer, left the company effective March 7, 2025. At the time of her departure, she was a named executive officer of the company.

2. 02

   West Pharmaceutical Services said that, under its standard severance policy, Ms. Reiss-Clark may receive severance benefits subject to her signing a release in favor of the company and its affiliates and complying with certain other covenants. The parties agreed on the terms of a Separation Agreement and Release.

3. 03

   Under the agreement, the company said it will provide Ms. Reiss-Clark with 1 years of salary continuation at her then-current salary of $489,500, continuation of welfare benefits at the then-current active employee rate, a 2025 payment of $57,526 (her pro-rated Annual Incentive Plan target), and outplacement services of up to $15,000.

4. 04

   The company said Ms. Reiss-Clark released all potential claims against the company to the extent permitted by law and agreed not to pursue litigation, in exchange for these benefits. She also reaffirmed her noncompetition and nonsolicitation obligations and agreed to cooperate with the company as needed, and the parties agreed to a nondisparagement provision.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.